UPDATE: Piper Jaffray Downgrades Osiris Therapeutics on DFU Data

In a report published on Tuesday, Piper Jaffray analyst Edward A. Tenthoff downgraded Osiris Therapeutics (NASDAQ: OSIR ) from Overweight to Neutral and increased the price target on the company from $14 to $21. In the report, Piper Jaffray stated, "Interim results from the Grafix trial in Diabetic Foot Ulcers